JPMorgan analyst Brian Cheng downgraded Mersana Therapeutics to Neutral from Overweight with a price target of $5, down from $11.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRSN:
- Mersana Therapeutics price target lowered to $10 from $16 at BTIG
- Mersana Plummets on Clinical Hold on Ovarian Cancer Trials
- Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials
- Mersana announces partial clinical hold on UP-NEXT, UPGRADE-A trials
- Guggenheim starts Mersana with a Buy on UpRi’s potential